Search Within

Matthew J Matasar

  1. "David Straus"
  2. "Craig Sauter"
  3. "Alison Moskowitz"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (3)
Groups
  1. Bone Marrow Transplant (17)
  2. Center for Hematologic Malignancies (17)
  3. Department of Medicine (17)
  4. Hematologic Malignancies, Division of (17)
  5. Lymphoma (17)
  6. Population Sciences Research Program (17)

More Groups

People
  1. Alison Moskowitz (17)
  2. Andrew Zelenetz (17)
  3. Ariela Noy (17)
  4. Craig Sauter (17)
  5. David Straus (17)
  6. Steven Horwitz (17)

More People

Years
  1. 2021 (2)
  2. 2020 (1)
  3. 2019 (3)
  4. 2017 (5)
  5. 2016 (3)
  6. 2015 (2)

More Years

Publications
  1. Blood (10)
  2. Hematological Oncology (3)
  3. Blood Advances (1)
  4. Haematologica (1)
  5. Journal of Clinical Oncology (1)
  6. Lancet Oncology (1)
Publishers
  1. American Society of Hematology (11)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Science, Inc. (1)
  5. Ferrata Storti Foundation (1)

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay
    Meeting Abstract

    Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save